INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

Pomerantz LLP is investigating potential securities fraud claims against Aardvark Therapeutics following the company's voluntary pause of its Phase 3 HERO trial in February 2026 due to cardiac safety concerns, and a subsequent FDA clinical hold placed on its ARD-101 drug in May 2026. The stock declined 56.2% following the initial announcement and an additional 32.1% after the FDA clinical hold.

05/26/2026, 4:58 PM • GlobeNewswire

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) stock plummeted 56% on March 2, 2026, after the company paused its Phase 3 HERO trial for ARD-101 due to serious cardiac safety concerns. The abrupt halt contradicts prior investor assurances about the drug's safety profile, prompting Hagens Berman to investigate potential securities law violations and misleading disclosures about the drug's development and FDA communications.

05/14/2026, 2:20 PM • GlobeNewswire

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman

Aardvark Therapeutics (AARD) stock plummeted 56% on March 2, 2026, after the company paused its Phase 3 HERO trial for ARD-101, citing serious cardiac safety concerns. The abrupt halt contradicted prior investor assurances about the drug's safety profile, prompting shareholder rights firm Hagens Berman to investigate potential securities law violations and investor fraud.

04/09/2026, 7:26 PM • GlobeNewswire

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

Aardvark Therapeutics' stock plummeted 56.2% to $5.47 per share on March 2, 2026, after the company announced a voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations in healthy volunteers at above-target therapeutic doses. The Portnoy Law Firm has initiated an investigation into possible securities fraud and may file a class action lawsuit on behalf of investors.

03/11/2026, 9:00 AM • GlobeNewswire

NOTICE TO DISREGARD -- Pomerantz LLP

Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. and FS KKR Capital Corp. The law firm is also issuing a retraction regarding a previous investigation notice about Ambarella, Inc.

03/05/2026, 12:55 PM • GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARD

Pomerantz Law Firm is investigating potential securities fraud claims against Aardvark Therapeutics following the company's voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations in safety monitoring. The announcement triggered a significant stock price decline of 56.2%, falling from $12.49 to $5.47 per share on March 2, 2026.

03/03/2026, 5:28 PM • GlobeNewswire

Stock Market Today: S&P 500, Dow, Nasdaq Futures Slide Amid US And Israel 'Operation Epic Furry' Against Iran— HKD, AARD, MDB In Focus (UPDATED)

U.S. stock futures fell sharply on Monday following geopolitical tensions with Iran, with the S&P 500, Dow Jones, and Nasdaq 100 all declining. The death of Iran's Supreme Leader and potential continuation of military strikes for weeks dampened market sentiment. Key movers included AMTD Digital surging 20% on strong revenue results, Aardvark Therapeutics plunging 53% after pausing a Phase 3 trial, and MongoDB dropping 2% ahead of earnings.

03/02/2026, 8:48 AM • Benzinga

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aardvark Therapeutics granted stock options to six new employees on February 9 and 11, 2026, totaling 152,338 shares with exercise prices of $13.48 and $12.67 respectively. The options vest over four years with standard 25% one-year cliff and monthly vesting thereafter, granted as inducement awards under the company's 2025 Inducement Equity Incentive Plan.

02/13/2026, 8:00 AM • GlobeNewswire

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aardvark Therapeutics granted stock options to four new employees in October and November 2025, with options ranging from 14,766 to 49,849 shares, vesting over four years under their Inducement Equity Incentive Plan.

11/03/2025, 5:55 PM • GlobeNewswire

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Aardvark Therapeutics granted stock options to two new employees between July 8-14, 2025, with each option vesting over four years and tied to the company's inducement equity incentive plan.

07/18/2025, 8:00 AM • GlobeNewswire